Skip to main content
Top
Published in: Journal of Translational Medicine 1/2009

Open Access 01-12-2009 | Methodology

The chemiluminescence based Ziplex® automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip® expression profiles

Authors: Michael CJ Quinn, Daniel J Wilson, Fiona Young, Adam A Dempsey, Suzanna L Arcand, Ashley H Birch, Paulina M Wojnarowicz, Diane Provencher, Anne-Marie Mes-Masson, David Englert, Patricia N Tonin

Published in: Journal of Translational Medicine | Issue 1/2009

Login to get access

Abstract

Background

As gene expression signatures may serve as biomarkers, there is a need to develop technologies based on mRNA expression patterns that are adaptable for translational research. Xceed Molecular has recently developed a Ziplex® technology, that can assay for gene expression of a discrete number of genes as a focused array. The present study has evaluated the reproducibility of the Ziplex system as applied to ovarian cancer research of genes shown to exhibit distinct expression profiles initially assessed by Affymetrix GeneChip® analyses.

Methods

The new chemiluminescence-based Ziplex® gene expression array technology was evaluated for the expression of 93 genes selected based on their Affymetrix GeneChip® profiles as applied to ovarian cancer research. Probe design was based on the Affymetrix target sequence that favors the 3' UTR of transcripts in order to maximize reproducibility across platforms. Gene expression analysis was performed using the Ziplex Automated Workstation. Statistical analyses were performed to evaluate reproducibility of both the magnitude of expression and differences between normal and tumor samples by correlation analyses, fold change differences and statistical significance testing.

Results

Expressions of 82 of 93 (88.2%) genes were highly correlated (p < 0.01) in a comparison of the two platforms. Overall, 75 of 93 (80.6%) genes exhibited consistent results in normal versus tumor tissue comparisons for both platforms (p < 0.001). The fold change differences were concordant for 87 of 93 (94%) genes, where there was agreement between the platforms regarding statistical significance for 71 (76%) of 87 genes. There was a strong agreement between the two platforms as shown by comparisons of log2 fold differences of gene expression between tumor versus normal samples (R = 0.93) and by Bland-Altman analysis, where greater than 90% of expression values fell within the 95% limits of agreement.

Conclusion

Overall concordance of gene expression patterns based on correlations, statistical significance between tumor and normal ovary data, and fold changes was consistent between the Ziplex and Affymetrix platforms. The reproducibility and ease-of-use of the technology suggests that the Ziplex array is a suitable platform for translational research.
Appendix
Available only for authorised users
Literature
1.
go back to reference Agarwal R, Kaye SB: Expression profiling and individualisation of treatment for ovarian cancer. Curr Opin Pharmacol. 2006, 6: 345-349. 10.1016/j.coph.2006.02.007.CrossRefPubMed Agarwal R, Kaye SB: Expression profiling and individualisation of treatment for ovarian cancer. Curr Opin Pharmacol. 2006, 6: 345-349. 10.1016/j.coph.2006.02.007.CrossRefPubMed
2.
go back to reference van't Veer LJ, Bernards R: Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008, 452: 564-570. 10.1038/nature06915.CrossRefPubMed van't Veer LJ, Bernards R: Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008, 452: 564-570. 10.1038/nature06915.CrossRefPubMed
3.
go back to reference Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD: Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol. 2006, 103: 405-416. 10.1016/j.ygyno.2006.03.056.CrossRefPubMed Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD: Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol. 2006, 103: 405-416. 10.1016/j.ygyno.2006.03.056.CrossRefPubMed
4.
go back to reference Konstantinopoulos PA, Spentzos D, Cannistra SA: Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 2008, 5: 577-587. 10.1038/ncponc1178.CrossRefPubMed Konstantinopoulos PA, Spentzos D, Cannistra SA: Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 2008, 5: 577-587. 10.1038/ncponc1178.CrossRefPubMed
5.
go back to reference Le Page C, Provencher D, Maugard CM, Ouellet V, Mes-Masson AM: Signature of a silent killer: expression profiling in epithelial ovarian cancer. Expert Rev Mol Diagn. 2004, 4: 157-167. 10.1586/14737159.4.2.157.CrossRefPubMed Le Page C, Provencher D, Maugard CM, Ouellet V, Mes-Masson AM: Signature of a silent killer: expression profiling in epithelial ovarian cancer. Expert Rev Mol Diagn. 2004, 4: 157-167. 10.1586/14737159.4.2.157.CrossRefPubMed
6.
go back to reference Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, Manderson EN, Provencher D, Mes-Masson AM: Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene. 2001, 20: 6617-6626. 10.1038/sj.onc.1204804.CrossRefPubMed Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, Manderson EN, Provencher D, Mes-Masson AM: Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene. 2001, 20: 6617-6626. 10.1038/sj.onc.1204804.CrossRefPubMed
7.
go back to reference Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J, Birrer MJ: A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008, 68: 5478-5486. 10.1158/0008-5472.CAN-07-6595.CrossRefPubMed Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J, Birrer MJ: A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008, 68: 5478-5486. 10.1158/0008-5472.CAN-07-6595.CrossRefPubMed
8.
go back to reference Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA: Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004, 22: 4700-4710. 10.1200/JCO.2004.04.070.CrossRefPubMed Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA: Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004, 22: 4700-4710. 10.1200/JCO.2004.04.070.CrossRefPubMed
9.
go back to reference Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, Rosen B, Minkin S, Squire JA, Macgregor PF: High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia. 2005, 7: 603-613. 10.1593/neo.04760.PubMedCentralCrossRefPubMed Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, Rosen B, Minkin S, Squire JA, Macgregor PF: High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia. 2005, 7: 603-613. 10.1593/neo.04760.PubMedCentralCrossRefPubMed
10.
go back to reference Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM: An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007, 25: 517-525. 10.1200/JCO.2006.06.3743.CrossRefPubMed Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM: An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007, 25: 517-525. 10.1200/JCO.2006.06.3743.CrossRefPubMed
11.
go back to reference Cody NA, Ouellet V, Manderson EN, Quinn MC, Filali-Mouhim A, Tellis P, Zietarska M, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN: Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene. 2007, 26: 618-632. 10.1038/sj.onc.1209821.CrossRefPubMed Cody NA, Ouellet V, Manderson EN, Quinn MC, Filali-Mouhim A, Tellis P, Zietarska M, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN: Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene. 2007, 26: 618-632. 10.1038/sj.onc.1209821.CrossRefPubMed
12.
go back to reference Stronach EA, Sellar GC, Blenkiron C, Rabiasz GJ, Taylor KJ, Miller EP, Massie CE, Al-Nafussi A, Smyth JF, Porteous DJ, Gabra H: Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. Cancer Res. 2003, 63: 8648-8655.PubMed Stronach EA, Sellar GC, Blenkiron C, Rabiasz GJ, Taylor KJ, Miller EP, Massie CE, Al-Nafussi A, Smyth JF, Porteous DJ, Gabra H: Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. Cancer Res. 2003, 63: 8648-8655.PubMed
13.
go back to reference Coticchia CM, Yang J, Moses MA: Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw. 2008, 6: 795-802.PubMedCentralPubMed Coticchia CM, Yang J, Moses MA: Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw. 2008, 6: 795-802.PubMedCentralPubMed
14.
go back to reference Le Page C, Ouellet V, Quinn MC, Tonin PN, Provencher DM, Mes-Masson AM: BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008, 17: 913-920. 10.1158/1055-9965.EPI-07-0692.CrossRefPubMed Le Page C, Ouellet V, Quinn MC, Tonin PN, Provencher DM, Mes-Masson AM: BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008, 17: 913-920. 10.1158/1055-9965.EPI-07-0692.CrossRefPubMed
15.
go back to reference Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, Horvath G: Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer. 2008, 123: 2130-2137. 10.1002/ijc.23758.CrossRefPubMed Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, Horvath G: Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer. 2008, 123: 2130-2137. 10.1002/ijc.23758.CrossRefPubMed
16.
go back to reference Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Lauter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG: ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006, 24: 4317-4323. 10.1200/JCO.2005.04.8397.CrossRefPubMed Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Lauter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG: ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006, 24: 4317-4323. 10.1200/JCO.2005.04.8397.CrossRefPubMed
17.
go back to reference Crijns AP, Duiker EW, de Jong S, Willemse PH, Zee van der AG, de Vries EG: Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. Int J Gynecol Cancer. 2006, 16 (Suppl 1): 152-165. 10.1111/j.1525-1438.2006.00503.x.CrossRefPubMed Crijns AP, Duiker EW, de Jong S, Willemse PH, Zee van der AG, de Vries EG: Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. Int J Gynecol Cancer. 2006, 16 (Suppl 1): 152-165. 10.1111/j.1525-1438.2006.00503.x.CrossRefPubMed
18.
go back to reference Chen JJ, Hsueh HM, Delongchamp RR, Lin CJ, Tsai CA: Reproducibility of microarray data: a further analysis of microarray quality control (MAQC) data. BMC Bioinformatics. 2007, 8: 412-10.1186/1471-2105-8-412.PubMedCentralCrossRefPubMed Chen JJ, Hsueh HM, Delongchamp RR, Lin CJ, Tsai CA: Reproducibility of microarray data: a further analysis of microarray quality control (MAQC) data. BMC Bioinformatics. 2007, 8: 412-10.1186/1471-2105-8-412.PubMedCentralCrossRefPubMed
19.
go back to reference Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, Collins PJ, Chu TM, Bao W, Fang H, Kawasaki ES, Hager J, Tikhonova IR, Walker SJ, Zhang L, Hurban P, de Longueville F, Fuscoe JC, Tong W, Shi L, Wolfinger RD: Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol. 2006, 24: 1140-1150. 10.1038/nbt1242.CrossRefPubMed Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, Collins PJ, Chu TM, Bao W, Fang H, Kawasaki ES, Hager J, Tikhonova IR, Walker SJ, Zhang L, Hurban P, de Longueville F, Fuscoe JC, Tong W, Shi L, Wolfinger RD: Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol. 2006, 24: 1140-1150. 10.1038/nbt1242.CrossRefPubMed
20.
go back to reference Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK, Puri RK, Schrf U, Thierry-Mieg J, Wang C, Wilson M, Wolber PK: The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006, 24: 1151-1161. 10.1038/nbt1239.CrossRefPubMed Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK, Puri RK, Schrf U, Thierry-Mieg J, Wang C, Wilson M, Wolber PK: The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006, 24: 1151-1161. 10.1038/nbt1239.CrossRefPubMed
22.
go back to reference Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM: From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer. 2006, 118: 1750-1758. 10.1002/ijc.21521.CrossRefPubMed Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM: From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer. 2006, 118: 1750-1758. 10.1002/ijc.21521.CrossRefPubMed
23.
go back to reference Arcand SL, Mes-Masson AM, Provencher D, Hudson TJ, Tonin PN: Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogeneously staining region. Mol Carcinog. 2004, 41: 17-38. 10.1002/mc.20038.CrossRefPubMed Arcand SL, Mes-Masson AM, Provencher D, Hudson TJ, Tonin PN: Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogeneously staining region. Mol Carcinog. 2004, 41: 17-38. 10.1002/mc.20038.CrossRefPubMed
24.
go back to reference Benoit MH, Hudson TJ, Maire G, Squire JA, Arcand SL, Provencher D, Mes-Masson AM, Tonin PN: Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. Int J Oncol. 2007, 30: 5-17.PubMed Benoit MH, Hudson TJ, Maire G, Squire JA, Arcand SL, Provencher D, Mes-Masson AM, Tonin PN: Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. Int J Oncol. 2007, 30: 5-17.PubMed
25.
go back to reference Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog. 2008, 47: 56-65. 10.1002/mc.20361.CrossRefPubMed Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog. 2008, 47: 56-65. 10.1002/mc.20361.CrossRefPubMed
26.
go back to reference Wojnarowicz PM, Breznan A, Arcand SL, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes. Int J Gynecol Cancer. 2008, 18: 963-975. 10.1111/j.1525-1438.2007.01134.x.CrossRefPubMed Wojnarowicz PM, Breznan A, Arcand SL, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes. Int J Gynecol Cancer. 2008, 18: 963-975. 10.1111/j.1525-1438.2007.01134.x.CrossRefPubMed
27.
go back to reference Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, Tonin PN: Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene. 2003, 22: 1568-1579. 10.1038/sj.onc.1206219.CrossRefPubMed Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, Tonin PN: Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene. 2003, 22: 1568-1579. 10.1038/sj.onc.1206219.CrossRefPubMed
28.
go back to reference Novak JP, Sladek R, Hudson TJ: Characterization of variability in large-scale gene expression data: implications for study design. Genomics. 2002, 79: 104-113. 10.1006/geno.2001.6675.CrossRefPubMed Novak JP, Sladek R, Hudson TJ: Characterization of variability in large-scale gene expression data: implications for study design. Genomics. 2002, 79: 104-113. 10.1006/geno.2001.6675.CrossRefPubMed
29.
go back to reference Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986, 1: 307-310.CrossRefPubMed Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986, 1: 307-310.CrossRefPubMed
30.
go back to reference Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Mol Carcinog. 2009, 48: 648-661. 10.1002/mc.20511.CrossRefPubMed Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Mol Carcinog. 2009, 48: 648-661. 10.1002/mc.20511.CrossRefPubMed
31.
go back to reference Pepper SD, Saunders EK, Edwards LE, Wilson CL, Miller CJ: The utility of MAS5 expression summary and detection call algorithms. BMC Bioinformatics. 2007, 8: 273-10.1186/1471-2105-8-273.PubMedCentralCrossRefPubMed Pepper SD, Saunders EK, Edwards LE, Wilson CL, Miller CJ: The utility of MAS5 expression summary and detection call algorithms. BMC Bioinformatics. 2007, 8: 273-10.1186/1471-2105-8-273.PubMedCentralCrossRefPubMed
32.
go back to reference Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage EH, O'Dwyer PJ, Livolsi VA, Johnson SW: Gene expression profiling of human ovarian tumours. Br J Cancer. 2006, 95: 1092-1100. 10.1038/sj.bjc.6603346.PubMedCentralCrossRefPubMed Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage EH, O'Dwyer PJ, Livolsi VA, Johnson SW: Gene expression profiling of human ovarian tumours. Br J Cancer. 2006, 95: 1092-1100. 10.1038/sj.bjc.6603346.PubMedCentralCrossRefPubMed
Metadata
Title
The chemiluminescence based Ziplex® automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip® expression profiles
Authors
Michael CJ Quinn
Daniel J Wilson
Fiona Young
Adam A Dempsey
Suzanna L Arcand
Ashley H Birch
Paulina M Wojnarowicz
Diane Provencher
Anne-Marie Mes-Masson
David Englert
Patricia N Tonin
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2009
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-7-55

Other articles of this Issue 1/2009

Journal of Translational Medicine 1/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.